Brian Park, PharmD

Drug Information Specialist https://www.empr.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

News

ProvayBlue Now Available in New Single-Dose Vials for Methemoglobinemia

Brian Park, PharmD

July 1, 2022

The new ProvayBlue presentation is supplied in a box of five 10mL single-dose vials; each vial contains 50mg of methylene blue.

Safety Alerts and Recalls

IBS-C Treatment Zelnorm Withdrawn From the Market Again

Brian Park, PharmD

June 30, 2022

The decision to remove Zelnorm from the market was strictly a business decision.

Drugs in the Pipeline

Aflibercept 16-Week Dosing Regimen for Diabetic Retinopathy Under Review

Brian Park, PharmD

June 29, 2022

The sBLA is supported by data from the phase 3 PANORAMA trial and the NIH-sponsored Protocol W trial.

News

FDA Extends Shelf-Life of Two COVID-19 Monoclonal Antibody Therapies

Brian Park, PharmD

June 29, 2022

This extension applies to all unopened vials that have been held in accordance with storage conditions detailed in the manufacturer’s labeling.

Drugs in the Pipeline

Novel Oral Drug Combo Fast Tracked for Obstructive Sleep Apnea

Brian Park, PharmD

June 28, 2022

The designation is supported by data from the phase 2 MARIPOSA study, which included adults with mild to moderate OSA.

Cannabis and its synthetic cannabinoids have been studied for medicinal properties across multiple d

Drugs in the Pipeline

Cannabis-Derived Oromucosal Spray Misses in MS Spasticity Trial

Brian Park, PharmD

June 28, 2022

The RELEASE MSS1 trial included adults with a confirmed diagnosis of any disease subtype of multiple sclerosis.

Drugs in the Pipeline

FDA Needs More Data on Tebipenem HBr for Complicated UTI

Brian Park, PharmD

June 28, 2022

In the CRL, the FDA stated that the application could not be approved in its present form and that an additional clinical trial would be required.

News

Qsymia Approved for Chronic Weight Management in Pediatric Patients

Brian Park, PharmD

June 28, 2022

The approval was based on data from a phase 4 study which included patients 12 to 17 years of age with a BMI at the 95th percentile or greater standardized for age and sex.